Anti-human VEGF (Bevacizumab Biosimilar) Size:5 mg Hemopoietic MBP

Hemopoietic MBP

four human TH mRNA splice variants (hTH1-hTH4) have been isolated

Number Component 50T Concentration Storage 1 PBS Buffer (powder) 2L x 2 20x RT 2 Antigen Retrieval Buffer 20ml 100x 2-8°C 3 Endogenous Peroxidase Blocking Buffer 3ml RTU 2-8°C 4 Blocking Buffer 3ml RTU 2-8°C 5 Primary Antibody (Human CD13 Recombinant Rabbit mAb) 6ml RTU 2-8°C 6 Secondary Antibody (Goat Anti-Rabbit IgG H&L / HRP) 6ml RTU 2-8°C 7 Chromogen Component A 0

both produced from a single protein precursor

Precautions

Anti-human VEGF (Bevacizumab Biosimilar) Size:5 mg Hemopoietic MBPApplication ELISA, Bioactivity: FACS, Functional assay, Research in vivo Reactivity Human Target Target Name VEGF Target Uniprot P15692 Overview Catalog# BIO0079SM Product Name Anti human VEGF (Bevacizumab Biosimilar) Specifications Conjugation None Clone# Bevacizumab Formulation 100 mM Pro Ac 20mM Arg pH 5. 0 Storage For long term storage, the produce should be stored at 20 or lower. Reconstitution Dissolve with sterile ddH2O Concentration